Fonds de solidarité FTQ invests $9.5 mln in DalCor Pharma
The Fonds de solidarité FTQ has invested about $9.5 million (US$7.5 million) in DalCor Pharmaceuticals, a Montréal-based developer of precision treatments for cardiovascular disease. The investment formed part of the company's recently closed $100 million Series B financing. DalCor, which emerged from research conducted at Montréal Heart Institute, is led by CEO Robert McNeil, the founder of U.S. life sciences venture capital firm Sanderling Ventures. The Fonds committed US$30 million to Sanderling Ventures Fund VII in September 2013.
26 April 2016•3 mins read
